Business Description
Apogee Therapeutics is a US-based clinical-stage biotech company focused on developing new antibody-based medicines for inflammatory and immune-related conditions, including atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease. Its leading drug candidate, Zumilokibart, is currently in Phase 2 trials for atopic dermatitis and Phase 1 trials for asthma and eosinophilic esophagitis, while several other candidates are progressing through early-stage testing for similar conditions. Founded in 2022 and headquartered in Waltham, Massachusetts, the company is building a pipeline aimed at addressing a range of conditions driven by an overactive immune system.
